The healthcare pricing platform is expanding access to Novo Nordisk’s newly approved oral GLP-1 for weight management, pairing transparent cash pricing with telehealth support nationwide.
GoodRx, the healthcare company that offers drug coupons for discounts on medications, unveiled that the recently FDA-approved Wegovy pill (oral semaglutide)—which is officially for sale in the US1—can now be found for cash price of $149 per month via the company’s 70,000 pharmacies across the United States.2
This price is for the two lowest doses (1.5 mg and 4 mg), but it’s important to note that these set prices are only valid through April 15, 2026. Following that date, a $199 monthly cash price will apply to the 4 mg dose. Meanwhile, the cash price for pills in 9 mg and 25 mg will run $299 per month.
Many consumers might be wondering what the next steps for treatment and access to the oral pill will be. Patients will soon be able to speak with a licensed HCP through its program “GoodRx for Weight Loss” to have their concerns addressed, including whether or not they are eligible and to receive an Rx. The telemedicine subscription is intended for those looking for weight management support.
The company notes that by having the Wegovy pill accessible on GoodRx, it is a step in the right direction for helping GLP-1s be more affordable for those looking to manage their weight.
“We’re excited to help consumers access one of the most anticipated weight-loss treatments on the market,” commented Wendy Barnes, president and CEO of GoodRx. “As new oral GLP-1 options emerge, GoodRx is uniquely positioned to support patients as they navigate their treatment choices. By combining transparent cash pricing with streamlined access to care and broad pharmacy availability, we're helping usher in a simpler, more consumer-friendly chapter in weight management treatment.”
This new version of Wegovy in pill form represents the first ever oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy that’s been approved for weight management. It also now marks the third formulation of Wegovy, expanding its available options.3
The industry may recall that the GLP-1 agonist was initially approved in June 2021 for chronic weight management in adults with obesity or overweight who have at least one related condition, such as hypertension, type 2 diabetes, or high cholesterol, alongside diet and exercise. In 2024, its label was further expanded to include adults with cardiovascular disease.
The approval is linked to results pertaining to both the OASIS trial program and the SELECT trial.3 The OASIS 4 trial—a 64-week, phase IIIb program—indicated that oral semaglutide 25 mg consumed once daily resulted in 16.6% mean weight loss when the treatment was followed by adult participants with either obesity or overweight with one or more comorbidities.
One in three participants also saw 20% or greater weight loss, and Novo notes that the weight loss is comparable to what was achieved via Wegovy’s injectable 2.4 mg version.
“We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them. For many of them, that wait is over as we can now offer the powerful efficacy of Wegovy in a once-daily pill that demonstrated about 17% weight loss, if all patients stayed on treatment,” noted Ed Cinca, Novo Nordisk’s senior vice president of marketing & patient solutions, in a recent press release.1 “Wegovy pill is here, and it represents a significant innovation as the first and only GLP-1 pill for weight loss. This moment is about changing what's possible in weight management, and to make that possible, we have worked to ensure Wegovy pill is affordable and accessible to those who need it, however they choose to receive their care.”
References
1. Novo Nordisk's Wegovy Pill, the First and Only Oral GLP-1 for Weight Loss on Adults, Now Broadly Available Across America. Novo Nordisk. January 5, 2026. Accessed January 5, 2026.
2. GoodRx Now Offers Novo Nordisk’s Cash Price for the Launch of the Wegovy Pill. Business Wire. January 5, 2026. Accessed January 5, 2026.
3. Saraceno N. FDA Approves Novo Nordisk’s Wegovy Pill, Marking First Oral GLP-1 for Weight Management. Pharmaceutical Commerce. December 24, 2025. Accessed January 5, 2026.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
